Compare Rocket Lab USA Inc (RKLB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Lab USA Inc vs Viatris Inc — how do they compare? Rocket Lab USA Inc trades at $63.64 (market cap $42.12B), while Viatris Inc trades at $16.43 (market cap $19.09B). The key difference: Rocket Lab USA Inc is far larger — about 2.2× Viatris Inc's market cap, and Viatris Inc pays a 2.89% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| RKLB | VTRS | |
|---|---|---|
Market Cap | $42.12B | $19.09B |
Sector | Technology | Health |
52-Week High | $150.23 | $17.86 |
52-Week Low | $39.48 | $9.49 |
Enterprise Value | $39.95B | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $65.87, up 2.51% today, but remains in a technical downtrend with bearish moving averages. The company reported Q2 2026 revenue of $234 million and a net loss, though it maintains a strong $2.36 billion backlog. Recent news highlights a rocket test failure and Neutron launch delay to 2027, alongside significant buying by Cathie Wood's ARK Invest.
Wall Street analysts are bullish with a $117.44 consensus target, but high valuation (P/S 48.82) and persistent losses pose risks. The stock offers growth potential in the expanding space economy, yet execution on Neutron and profitability timeline are critical near-term catalysts and challenges.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, showing mixed technical signals with a bullish moving average trend but neutral oscillators. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.69 exceeding expectations by 14.8%. However, fundamental challenges persist with negative net income margins and declining revenue trends from $16.3B in 2022 to $14.3B in 2025.
The outlook remains cautious despite recent operational improvements. While cost-cutting initiatives and strategic divestitures show progress, the stock faces headwinds from pricing pressure in generic drugs and high debt levels. Analyst consensus leans neutral with 62% hold ratings, reflecting uncertainty about the company's turnaround trajectory amid competitive and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
